Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
暂无分享,去创建一个
Placido Bramanti | Emanuela Mazzon | E. Mazzon | P. Bramanti | Cristina Guarnera | Cristina Guarnera
[1] Jeffrey A. Cohen,et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.
[2] S. Breslin. Cytokine-release syndrome: overview and nursing implications. , 2007, Clinical journal of oncology nursing.
[3] A. Compston,et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[4] R. Schmidt,et al. Cancer therapy-associated CNS neuropathology: an update and review of the literature , 2006, Acta Neuropathologica.
[5] L. Durelli,et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab , 2017, Multiple sclerosis.
[6] T. Tanizawa,et al. Disseminated necrotizing leukoencephalopathy following chemoradiation therapy for acute lymphoblastic leukemia , 2006, Radiation Medicine.
[7] G. Hale,et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.
[8] K. Selmaj,et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.
[9] A. Coles,et al. Mode of action and clinical studies with alemtuzumab , 2014, Experimental Neurology.
[10] J. Zajicek,et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis , 2008, Journal of Neurology.
[11] A. Compston,et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis , 1994, The Lancet.
[12] H. Sakamaki,et al. Disseminated necrotizing leukoencephalopathy following irradiation and methotrexate therapy for central nervous system infiltration of leukemia and lymphoma. , 1993, Radiation medicine.
[13] D. Margolin,et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. , 2014, The Journal of clinical endocrinology and metabolism.
[14] V. Radhakrishnan,et al. Disseminated necrotizing leukoencephalopathy following low‐dose oral methotrexate , 2007, European journal of neurology.
[15] D. Margolin,et al. Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program. , 2015, International journal of MS care.
[16] Christian Confavreux,et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.
[17] A. Wilkins,et al. Thyroid papillary carcinoma after alemtuzumab therapy for MS , 2014, Journal of Neurology.
[18] W. Brück,et al. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis , 2016, Acta Neuropathologica Communications.
[19] T. Vartanian,et al. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis , 2018, Multiple sclerosis.
[20] Jeffrey A. Cohen,et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients , 2016, Neurology.
[21] M. Ban,et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). , 2009, The Journal of clinical investigation.
[22] M. Sheikh-Taha,et al. Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis , 2017, Multiple sclerosis.
[23] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .
[24] J. Halper,et al. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. , 2010, Journal of infusion nursing : the official publication of the Infusion Nurses Society.
[25] H. Wiendl,et al. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis , 2016, Multiple sclerosis.
[26] H. Sullivan,et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial , 2012, Neurology.
[27] F. Weber,et al. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases , 2015, International journal of molecular sciences.
[28] J. Zajicek,et al. Melanoma following treatment with alemtuzumab for multiple sclerosis , 2009, European journal of neurology.
[29] A. Matucci,et al. Acute infusion reactions induced by monoclonal antibody therapy , 2011, Expert review of clinical immunology.
[30] D. Annane,et al. Multifocal necrotizing leukoencephalopathy in septic shock , 2002, Critical care medicine.
[31] 서정헌,et al. 반도체 공정 overview , 2001 .
[32] T. Korn,et al. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis. , 2016, JAMA neurology.
[33] H. Waldmann,et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. , 1994, Bone marrow transplantation.
[34] J. Lechner-Scott,et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.
[35] L. Kasten,et al. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program , 2015 .
[36] F. Bagnato,et al. Alemtuzumab for the treatment of multiple sclerosis , 2018, Expert opinion on biological therapy.
[37] A. Compston,et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis , 1999, Annals of neurology.
[38] A. Compston,et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[39] N. Robertson,et al. Alemtuzumab for Multiple Sclerosis , 2016, Current Neurology and Neuroscience Reports.
[40] A. Compston,et al. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench , 2004, Clinical Neurology and Neurosurgery.
[41] J. Byrd,et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Havrdová,et al. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use , 2015, Therapeutic advances in neurological disorders.
[43] Wellbutrin,et al. Prescribing Information , 2015, European journal of haematology.